1. Home
  2. IHG vs INCY Comparison

IHG vs INCY Comparison

Compare IHG & INCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IHG
  • INCY
  • Stock Information
  • Founded
  • IHG 1777
  • INCY 1991
  • Country
  • IHG United Kingdom
  • INCY United States
  • Employees
  • IHG N/A
  • INCY N/A
  • Industry
  • IHG Hotels/Resorts
  • INCY Biotechnology: Commercial Physical & Biological Resarch
  • Sector
  • IHG Consumer Discretionary
  • INCY Health Care
  • Exchange
  • IHG Nasdaq
  • INCY Nasdaq
  • Market Cap
  • IHG 16.5B
  • INCY 13.4B
  • IPO Year
  • IHG N/A
  • INCY 1993
  • Fundamental
  • Price
  • IHG $116.12
  • INCY $58.98
  • Analyst Decision
  • IHG Sell
  • INCY Hold
  • Analyst Count
  • IHG 2
  • INCY 20
  • Target Price
  • IHG N/A
  • INCY $73.06
  • AVG Volume (30 Days)
  • IHG 225.5K
  • INCY 1.9M
  • Earning Date
  • IHG 01-01-0001
  • INCY 04-29-2025
  • Dividend Yield
  • IHG 2.43%
  • INCY N/A
  • EPS Growth
  • IHG N/A
  • INCY N/A
  • EPS
  • IHG 3.85
  • INCY 0.10
  • Revenue
  • IHG $4,923,000,000.00
  • INCY $4,413,226,000.00
  • Revenue This Year
  • IHG N/A
  • INCY $12.28
  • Revenue Next Year
  • IHG $6.17
  • INCY $9.20
  • P/E Ratio
  • IHG $28.19
  • INCY $536.75
  • Revenue Growth
  • IHG 6.47
  • INCY 17.13
  • 52 Week Low
  • IHG $91.57
  • INCY $52.81
  • 52 Week High
  • IHG $137.25
  • INCY $83.95
  • Technical
  • Relative Strength Index (RSI)
  • IHG 64.67
  • INCY 44.09
  • Support Level
  • IHG $112.00
  • INCY $57.77
  • Resistance Level
  • IHG $118.13
  • INCY $62.87
  • Average True Range (ATR)
  • IHG 1.73
  • INCY 1.78
  • MACD
  • IHG 1.66
  • INCY 0.20
  • Stochastic Oscillator
  • IHG 87.72
  • INCY 36.23

About IHG Intercontinental Hotels Group

InterContinental Hotels Group operates 987,000 rooms across 19 brands addressing the midscale through luxury segments, as of Dec. 31, 2024. Holiday Inn and Holiday Inn Express constitute the largest brand, while Hotel Indigo, Even, Hualuxe, Kimpton, and Voco are newer lifestyle brands experiencing strong demand. The company launched a midscale brand, Avid, in 2017 and closed on a 51% stake in Regent Hotels in 2018. It acquired Six Senses in 2019 and launched another midscale brand, Garner, in 2023. Managed and franchised represent 99% of total rooms. As of Dec. 31, 2024, the Americas represented 53% of total rooms, with Greater China accounting for 20% and Europe, Asia, the Middle East, and Africa making up 27%.

About INCY Incyte Corp.

Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.

Share on Social Networks: